Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This general anesthetic regimen is a multi-drug combination protocol utilized by **China Medical University** in clinical research, specifically the GIM-POD study, to induce and maintain anesthesia in patients undergoing gastrointestinal surgery. The induction phase consists of **etomidate** (a carboxylated imidazole hypnotic), **midazolam** (a benzodiazepine), **sufentanil** (a potent opioid analgesic), and **cisatracurium** (a non-depolarizing neuromuscular blocking agent). Maintenance of anesthesia is achieved through the inhalation of **sevoflurane** (a halogenated ether) supplemented with continuous sufentanil administration. This combination is designed to provide a balanced state of hypnosis, amnesia, analgesia, and muscle relaxation while minimizing hemodynamic fluctuations during major surgical procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etomidate + midazolam + sufentanil + cisatracurium + sevoflurane.